Skip to main content
SpringerLink
Log in

The US FDA has placed a clinical hold on HEPLISAV, an investigational hepatitis B vaccine

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Dynavax Technologies Corporation, Merck & Co Inc.Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV. Media Release: 18 Mar 2008. Available from: URL: http://www.dynavax.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The US FDA has placed a clinical hold on HEPLISAV, an investigational hepatitis B vaccine. React. Wkly. 1196, 4 (2008). https://doi.org/10.2165/00128415-200811960-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200811960-00009

Keywords

Search

Navigation